GOODIX
Goodix (Shanghai Stock Exchange:603160), the premier developer of human interface and biometric solutions for mobile devices, announced today that Huawei P10 and P10 Plus, flagship smartphones of 2017 just launched at Mobile World Congress 2017, are using Invisible Fingerprint Sensor (IFS™) from Goodix.
Huawei’s P10 and P10 Plus smartphones have stylish, integrated screen panel design. The Home key has IFS™ embedded under the screen panel, allowing fingerprint authentication through the glass. IFS™ from Goodix enables the elegant and slim design of P10 and P10 Plus while providing secure and easy-to-use fingerprint authentication. This safeguards the smartphone and secures mobile transactions.
World’s first IFS™ solution meets Huawei’s design needs
Traditionally, a button needs to be placed on the front or at the back of a smartphone in order to install a fingerprint sensor. This means manufacturers need to open a hole on the glass panel for the button. This occupies space, affects the overall phone design and increases the complexity of manufacturing process. Goodix’s IFS™ addresses these issues by seamlessly integrating the sensor right under the glass panel without the need to drill a hole and place a button.
Goodix and Huawei share the same vision of innovating latest technologies to fulfill people’s desires and needs. The longstanding partnership between the two companies is a great success. Prior to the P10 and P10 Plus, a number of Huawei smartphones already use various Goodix’s fingerprint authentication and touchscreen controller solutions. The two companies will continue to innovate to provide safer, more convenient and intelligent technology to mobile users.
IFS™ gives manufacturers more flexibility to develop stylish, slim phone designs. It also supports thick glass panels and improves the water and dust resistance. All this combines to deliver a better user experience and higher reliability.
From R&D to successful commercialization
To authenticate fingerprints through glass panels poses many technical challenges and requires the redesign of circuits and the software algorithm. Goodix has been driving the development process from R&D to commercialization. Since IFS™ was launched in 2014, the company has worked closely with glass panel manufacturers and fingerprint module suppliers to ensure that the functionality, performance, reliability and supply of IFS can meet the various demands of mobile device manufacturers.
The successful commercialization of IFS™ reinforces Goodix as a global leader in biometric technology. This leading position is well recognized by global mobile brands. As of January 2017, Goodix has applied for and received more than 900 patents. The strong R&D capability propels Goodix forward to continue to innovate for mobile users. IFS™ won a Consumer Electronics Show (CES) Innovation Award in 2016, and Goodix was the first Chinese integrated circuit (IC) company to ever win this honor.
About Goodix:
Goodix , a premier developer and provider of fingerprint and touchscreen solutions for mobile phones, tablets and wearables, currently holds a diversified portfolio of fingerprint authentication solutions that provides excellent flexibility to suit the varying preferences from consumers and partners such as Live Finger Detection™, Invisible Fingerprint Sensor (IFS™), Glass-covered and Coating button sensors. In addition, Goodix has been actively involved in assisting Alipay and China UnionPay with reviewing industry standards for fingerprint authentication. An increasing number of top-tier handset manufacturers adopting fingerprints and touch solutions from the company. On October 17, 2016, Goodix was listed on the Shanghai Stock Exchange, the stock code is 603160.
Goodix™ and Invisible Fingerprint Sensor (IFS™) are trademarks of Goodix in China and other countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006232/en/
Contact:
FleishmanHillard, on behalf of Goodix
Alisa Davis, 415-318-4086
Alisa.davis@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom